[Alpha Biz=(Chicago) Reporter Kim Jisun] Merck Life Science, a leading global science and technology company, said on the 21st that it has decided to invest 300 million euros or about 430 billion won to build a new bioprocessing production center in Daejeon.
On May 3, 2023, Merck Life Science signed a memorandum of understanding (MOU) with the Ministry of Trade, Industry and Energy and Daejeon Metropolitan City to establish raw material production facilities used in the new Asia-Pacific bio process. The decision is an extension of the memorandum of understanding signed earlier, establishing a specific size and plan for investment.
This investment is the largest investment Merck Lifescience has ever made in the Asia-Pacific region. Merck's willingness to contribute to the fast-growing biotechnology industry in the Asia-Pacific region was reflected. Merck Lifescience expects the investment to create about 300 more jobs by the end of 2028.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
